A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Clinical data as well as animal and cell studies indicate that certain antidiabetic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), exert therapeutic effects in Alzheimer's disease (AD) by modulating amyloid-β peptide (Aβ) meta…
AIMS: Managing patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) is challenging. While sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) show cardiovascular b…
UNLABELLED: Glucagon-like peptide-1 receptor (Glp1r) agonists have transformed obesity treatment, but weight loss responses to these drugs vary widely. Elucidating behavioral and metabolic phenotypes throughout Glp1r agonist treatment could identify…
Innovations in liquid chromatography stationary phase media can address emerging peptide separation and purification challenges. Herein, we report the synthesis of novel carbon microbeads from natural micrographite flakes as the starting material (re…
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated efficacy for weight loss and glycemic control in patients with obesity and type 2 diabetes mellitus, but data are limited for patients with end-stage kidney disease on dialysis…
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a well-established agent in managing patients with high cardiovascular risk. Initially, a formulation was introduced for weekly subcutaneous administration that demonstrated good tolerabilit…
BACKGROUND: Many patients seek body contouring surgery (BCS) to address excess skin following significant weight loss (WL), including from GLP-1 receptor agonists such as semaglutide. Optimal BCS timing is crucial, as postoperative weight fluctuation…
Given the documented increased risk of non-arteritic ischaemic optic neuropathy (NAION), the widespread use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has raised concerns regarding their ophthalmic safety. This study presents a unique c…
Introduction Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are used in the treatment of type 2 diabetes mellitus and obesity. A side effect of GLP1-RAs is delayed gastric emptying, which could increase the risk of pulmonary aspiration. This ex…
PURPOSE: Sleeve gastrectomy (LSG) is effective, but weight regain (WR) and variable hormonal responses challenge long-term outcomes. This study evaluated long-term weight and incretin trajectories after LSG in adolescents and assessed the impact of a…
BACKGROUND: Glucagon-like peptide 1 (GLP-1) agonists like semaglutide have risen significantly in use in recent years as a therapeutic option for the management of obesity. Popular media serves as an information source for many patients, and dependin…
In diabetic patients, treatment with GLP-1 (Glucagon-Like Peptide-1) and dual GLP-1/GIP (gastric inhibitory polypeptide) agonists, such as, respectively, semaglutide and tirzepatide, is effective in lowering blood sugar and reducing weight. However,…
: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of type 2 diabetes and obesity. While their metabolic benefits are well-established, their potential effects on vestibular function remain unexplored. This study…
There is growing evidence suggesting that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is effective in preventing and treating chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2D). The Evaluate Renal Func…
IMPORTANCE: Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D). OBJECTI…
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained popularity in recent years. Consequently, Semaglutide prescription rates have increased for both its indicated and off-label uses. A possible link between GLP-1 RAs and suic…
Introduction This study aims to evaluate the risk of residual gastric content (RGC) among patients taking semaglutide/tirzepatide undergoing an esophagogastroduodenoscopy (EGD). Methods A retrospective observational study was conducted from 2024 to 2…